A Study in Healthy Men to Test Whether Rifampicin Influences the Amount of BI 894416 in the Blood

NCT04060719 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2023-08-14

Study results available
· View outcomes & findings →

Summary

The main objective of this trial is to investigate the effect of rifampicin on the pharmacokinetics of BI 894416.

Conditions

  • Healthy

Interventions

DRUG

BI 894416

tablet

DRUG

Rifampicin

tablet

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-04
Primary Completion
2019-10-17
Completion
2019-10-17
FDA Drug
Yes

Countries

  • Germany

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04060719 on ClinicalTrials.gov